Gen-011

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

GEN-011 is an experimental treatment being studied for certain advanced solid tumors, including some types of cancer similar to colorectal cancer. It is a type of personalized immunotherapy called adoptive cell therapy (ACT). This means that doctors take some of your own immune cells (T cells), modify them in a lab to better recognize cancer cells, and then put them back into your body to fight the cancer. The specific targets for GEN-011 are identified from your own tumor using a special tool called ATLAS™, which finds neoantigens (unique markers on cancer cells). GEN-011 is currently in early-phase clinical trials (Phase 1) to determine its safety and how well it works. It is not yet approved for treating colorectal cancer or any other cancer.

Mechanism of Action

GEN-011 is a personalized adoptive cell therapy (ACT). It involves collecting a patient's own T cells (a type of immune cell). Using a technology called ATLAS™, researchers identify unique markers (neoantigens) on the patient's tumor cells that the immune system can recognize. These neoantigens are used to stimulate and select the patient's T cells in the lab, enhancing their ability to target and kill cancer cells. The modified T cells (the adoptive cell product) are then infused back into the patient. In clinical trials, GEN-011 is often given with interleukin-2 (IL-2), which helps boost the activity of the infused T cells.

Side Effects

GEN-011 is an investigational drug in early-phase clinical trials. Specific side effects related to GEN-011 are still being evaluated. As it involves modifying and re-infusing a patient's own cells Potential side effects could include those associated with the cell collection process (apheresis) The cell modification process The infusion itself And the use of costimulatory agents like interleukin-2 (IL-2). IL-2 can cause side effects like flu-like symptoms Nausea Diarrhea And fatigue. More specific side effects related to GEN-011 will become clearer as trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04596033 Phase 1
Archived
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
768 trials
Leucovorin
Other Medications
627 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.